

*In the name  
of God...*






Royan Institute

# Application of Artificial Oocyte Activation in Assisted reproductive technology


**M.H Nasr-Esfahani (PhD)**

1. Department of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
2. Isfahan Fertility and Infertility Center, Isfahan, Iran.



[Email: mh.nasr-esfahani@royaninstitute.org](mailto:mh.nasr-esfahani@royaninstitute.org) & [nasr.royan@gmail.com](mailto:nasr.royan@gmail.com)



**In vitro Fertilization**



**Intra Cytoplasmic Sperm Injection**



## When is ICSI recommended, and for who?

- There is low sperm count and/or poor sperm motility and/or poor abnormal morphology;
- Previous IVF treatments resulted in none or very few fertilized eggs;
- Surgical sperm retrieval is required (due to a medical condition, vasectomy or an extremely low sperm count);
- Embryo testing is being performed, such as Pre-Implantation Genetic Testing for Aneuploidy (PGT-A) ;
- Frozen sperm is being used that may be of low quality.

Reported ICSI fertilization rates are between **70 and 80%**, usually about **10% higher** than that of conventional IVF methods. Unfortunately, TFF still occurs in ICSI cycles.



Total fertilization failure (TFF), which is the failure of fertilization in all oocytes, occurs in **5–10% of all cycles in Europe and the USA**.



TFF after ICSI is **defined** as **the lack of male and female pronuclei formation**, a sign of fertilization, at the standard checking time of  $17 \pm 1$  h post ICSI, in all oocytes retrieved during a cycle.

TFF rates depend heavily on the number of mature (MII) oocytes available.


- One retrospective study found a TFF rate of **2.14%** in cycles with 3 or more MII oocytes and a TFF rate of **17.4%** in cycles with 1 or 2 MII oocytes available.



Excluding cycles with diminished oocyte reserve, TFF rates were found to be 1–5%.




- Among the TFF cases, roughly **10% were due to technical** errors where sperm DNA lie outside of the oocyte.
- A majority of the cases point to **failed oocyte activation**.



Technical errors

**While the main etiology of TFF has been extensively reported as oocyte activation failure, mechanisms underlying oocyte activation failure have yet to be elucidated.**






**First:** It is often unclear whether the defect comes from the sperm, the oocyte, or both.

**Second:** Proteins, organelles, and metabolic pathways of both gametes need to function properly in cascades of cellular events in a successful oocyte activation.


➤ **Mouse oocyte activation tests can exclude sperm deficiency. Yet, in cases of oocyte deficiency, it remains challenging to conclude on which level in the cascade there is a failure.**

**Third:** Calcium oscillations in fertilized oocytes have been investigated in TFF cases because of their importance in oocyte development and activation leading up to successful fertilizations.






Fertilization




Oocyte activation mechanism and its consequences



**a** Blocking IP3Rs results in loss of high-amplitude, organized Ca<sup>2+</sup> waves. Localized low-amplitude Ca<sup>2+</sup> spikes were observed, likely mediated by RyRs.

Generation of two types of calcium waves. Inositol triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) are two main receptors in cells that mediate the generation of Ca<sup>2+</sup> waves.


**a:** IP3Rs initiate and maintain both spontaneous and Ca<sup>2+</sup>-induced Ca<sup>2+</sup> waves. Crosstalk between IP3Rs and RyRs shape the characteristics of Ca<sup>2+</sup> waves.



Processing of oocytes in assisted reproductive technology (ART) alters natural  $\text{Ca}^{2+}$  oscillatory patterns post fertilization. **These alternations might be due to the speed at which sperm factors are released into oocytes, with the effects modified by different immobilization and injection techniques.**

- 1: Different oscillation patterns have been observed in human in vitro fertilization (IVF) and ICSI protocols.
- 2: Calcium oscillation patterns also differ significantly from species to species.
- 3: Also, oocyte responses to such oscillations alter as a process of **aging**.

Whether differences in oscillation patterns hold clinical significance remains unclear.




The importance of calcium signaling in TFF can be seen in the development of various artificial oocyte activation (AOA) methods. These methods attempt to raise oocyte cytoplasmic calcium level to achieve a higher fertilization rate in cases of TFF where oocyte activation failure is suspected.

**Natural activators:** Phospholipase C-zeta (PLC $\zeta$ )

**Non-natural activators:**

- Ca<sup>2+</sup> ionophore A23187 (calcimycin);
- Ionomycin
- Strontium chloride

AND electrical







Natural activator: Phospholipase C-zeta (PLC $\zeta$ )

# SCIENTIFIC REPORTS



OPEN

## Sperm-borne phospholipase C zeta-1 ensures monospermic fertilization in mice



Kaori Nozawa<sup>1,2</sup>, Yuhkoh Satouh <sup>1</sup>, Takao Fujimoto<sup>1,3</sup>, Asami Oji<sup>1,3</sup> & Masahito Ikawa <sup>1,2,3,4</sup>




Sperm entry in mammalian oocytes triggers intracellular Ca<sup>2+</sup> oscillations that initiate resumption of


Received: 1 September 2017

Accepted: 3 January 2018

Published online: 22 January 2018




**a****b****c**



These results suggest that mammalian spermatozoa have a primitive oocyte activation mechanism and that PLCζ1 is a SOAF that ensures oocyte activation steps for monospermic fertilization in mammals.

**Conclusion:** Although ICSI ensures monospermic fertilization, oocyte activation failures still occur and have been reported as a cause of unexplained infertility. As we observed polyspermy in *Plcz1* mutant mice, such patients might have polyspermy in vivo as well as oocyte activation failure following ICSI. If it is caused by male infertility, this form could possibly be treated by a combination of ICSI and PLCζ1 complementation in vitro.



The establishment of appropriate methods for egg-activation by human PLCZ1 RNA injection into human oocyte

**Authors:** Takashi Yamaguchi, Masahiko Ito, Keiji Kuroda, Satoru Takeda, Atsushi Tanaka

PII: S0143-4160(16)30191-9

DOI: <http://dx.doi.org/doi:10.1016/j.ceca.2017.03.002>

Reference: YCECA 1839


To appear in: Cell Calcium

Received date: 8-11-2016

Revised date: 3-3-2017


Accepted date: 3-3-2017






For the application of PLCZ1 **to clinical use**, the pattern of Ca<sup>2+</sup> responses and developmental rate by comparing PLCZ1 RNA injection methods with the other current methods, such as cytosolic aspiration, electrical stimulation and ionomycin treatment in human oocytes.

- I. The pattern of Ca<sup>2+</sup> oscillations after PLCZ1 RNA injection exhibited similar characteristics to that after ICSI treatment.
- II. Optimal concentration of human PLCZ1 RNA to activate the human oocytes was determined.
- III. Human PLCZ1 RNA is a better therapeutic agent to rescue human oocytes from failed activation, leading to normal and efficient development.



Optimal concentration of human PLCZ1 RNA





# Conclusion

Human PLCZ1 RNA is a better therapeutic agent to rescue human oocytes from failed activation, leading to normal and efficient development.

## Quantitative expression of phospholipase C zeta, as an index to assess fertilization potential of a semen sample

S. Aghajanzpour<sup>1,2</sup>, K. Ghaedi<sup>1,2</sup>, A. Salamian<sup>1</sup>, M.R. Deemeh<sup>1,3</sup>,  
M. Tavalaei<sup>1</sup>, J. Moshtaghian<sup>2</sup>, J. Parrington<sup>4</sup>,  
and M.H. Nasr-Esfahani<sup>1,3,5,\*</sup>



## ORIGINAL ARTICLE

## Correspondence:

Mohammad H. Nasr-Esfahani, Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.  
E-mail: mh.nasr-esfahani@royaninstitute.org

## Keywords:

fertilization, globozoospermia, PAWP, PLC $\zeta$ , pregnancy, TR-KIT

Received: 17-Sep-2015

Revised: 1-Feb-2016

Accepted: 3-Feb-2016

doi: 10.1111/andr.12179

## Expression profile of PLC $\zeta$ , PAWP, and TR-KIT in association with fertilization potential, embryo development, and pregnancy outcomes in globozoospermic candidates for intra-cytoplasmic sperm injection and artificial oocyte activation

<sup>1</sup>M. Tavalaei and <sup>1,2</sup>M. H. Nasr-Esfahani

<sup>1</sup>Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran, and <sup>2</sup>Isfahan Fertility and Infertility Center, Isfahan, Iran






Table 3 Characteristics of each globozoospermic cases and their ICSI-AOA clinical outcomes

	G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12
Male age (years)	28	36	35	36	32	37	44	23	26	35	35	35
Female age (years)	26	33	28	23	35	30	41	24	22	28	32	32
No. oocytes retrieved	4	13	12	23	30	13	3	12	8	7	8	10
No. MII oocytes	2	9	7	19	26	11	2	11	8	6	8	6
No. fertilized oocytes	2	8	6	14	16	6	1	5	3	2	2	1
Fertilization rate (%)	100	89	85.7	73.7	61.5	54.54	50	45.46	37.5	33.34	25	17
Cleavage rate (%)	100	62.5	100	50	18.7	66	100	40	66	100	100	100
No. embryos transferred	2	2	3	2	2	2	1	3	3	2	2	1
Clinical pregnancy	–	+	+	–	–	+	–	+	–	+	–	–
Sac number		1	1			2		1		2		
Implantation rate (%)	00	50	33.4	00	00	100	00	33.4	00	100	00	00
Live birth		1 M	1 FM			00		1		2 FM		
Abortion rate (%)						2 FM						

M, Male; FM, Female; G, globozoospermia.

**High fertilization (56.06%) and pregnancy (41.7%) rates accomplished in this study following ICSI-AOA indicated that expression profiles of PLCf and PAWP were low in globozoospermic individuals, and ICSI combined with artificial oocyte activation could mimic physiological calcium changes which occur during fertilization.**



Title: Expression of sperm PLC $\zeta$  and clinical outcomes of ICSI-AOA in men affected by globozoospermia due to DPY19L2 deletion.

Author: Marziyeh Tavalaei, Michail Nomikos, F. Anthony Lai, Mohammad Hossein Nasr-Esfahani.

PII: S1472-6483(17)30708-3

DOI: <https://doi.org/10.1016/j.rbmo.2017.12.013>

Reference: RBMO 1872

To appear in: Reproductive BioMedicine Online

Received date: 24-6-2017

Revised date: 28-11-2017

Accepted date: 7-12-2017





The expression of PLCzeta at RNA and protein levels in globozoospermic men with DPY19L2 deletion was significantly lower compared with fertile men ( $n = 32$ ).

Fertilization rate in globozoospermic couples following ICSI-AOA was significantly lower compared with fertile men (53.14% versus 87.64%,  $P < 0.001$ ).

However, **implantation** (26.2%) and **pregnancy** (53.8%) rates were not jeopardized by DPY19L2 deletion in these couples.



Non-natural activator:

➤ Electrical

**FERTILITY AND STERILITY®**

*VOL. 72, NO. 3, SEPTEMBER 1999*

Copyright ©1999 American Society for Reproductive Medicine

Published by Elsevier Science Inc.

Printed on acid-free paper in U.S.A.

**REPRODUCTIVE BIOLOGY**

**Electrical activation and in vitro  
development of human oocytes that fail to  
fertilize after intracytoplasmic sperm  
injection**

Electric field induces micropores in gamete membranes that facilitate  $\text{Ca}^{2+}$  influx.

One group found that single or multiple electrical pulse(s) was able to activate oocytes that showed no evidence of fertilization 16–24 h after ICSI.

In this study, **human** oocytes that displayed two pronuclei and extruded a second polar body within 16 h were considered to have fertilized normally.

- One electrical pulse fertilized oocyte at a rate of 70%;
- Three electrical pulses fertilized oocytes at a rate of 78%.

**Despite the relatively high fertilization rate, however, only 11% of the oocytes fertilized with the assistance of **three electrical pulses** developed to early blastocyst stage.**

The study did not analyze calcium transients induced by electrical pulses or correlate the difference in fertilization rate with corresponding calcium responses.

Non-natural activators:

➤ Chemical



Chemical agents such as calcium ionophores are generally assumed to directly facilitate the transport of Ca<sup>2+</sup> across the plasma membrane.

**Table 2** Results of assisted oocyte activation (AOA) on human oocyte activation rate and rate to blastocyst formation

Activation agent	Ca <sup>2+</sup> response	Protocol	Oocyte activation rate	Rate to blastocyst	Study
Ionomycin	Single transients	10 μM for 10 min (2 exposures, 30-min interval); human sperm with low or complete failed fertilization	74.2%	N/A	[16]
Calcium ionophore A23187	Single transients	5% for 5 min followed by 2 mM 6-DMAP incubation	75.4%	9.1%	[62]
SrCl <sub>2</sub>	Oscillatory signaling	10 mM for 20 min followed 2.5 mM 6-DMAP incubation	46.8%	4.8%	
Ionomycin	Single transients	10 μM for 10 min (2 exposures, 30 min interval) + 0.1 mol/L CaCl <sub>2</sub> ; human globozoospermic sperm ready to use for 15 min (1 exposure);	30.0%	N/A	[15]
Calcimycin	Single transients	human globozoospermic sperm	11.8%		
Electric field	Single transients	1.36–1.50 kV/cm for 40–60 ms (1 pulse)	70%	8%	[63]
	Oscillatory signaling	1.36–1.50 kV/cm for 40–60 ms (3 pulses, 15–20-min interval)	78%	11%	
SrCl <sub>2</sub>	Oscillatory signaling	10 mM for 1 h (1 exposure); human sperm with low or complete failed fertilization	61.7%	25.7%	[64]

# Meta analysis studies



Hum. Reprod. Advance Access published June 16, 2015

Human Reproduction, Vol.0, No.0 pp. 1–11, 2015

doi:10.1093/humrep/dev136

human  
reproduction

**META-ANALYSIS** *Embryology*

# Artificial oocyte activation to improve reproductive outcomes in women with previous fertilization failure: a systematic review and meta-analysis of RCTs

Ioannis A. Sfontouris<sup>1</sup>, Carolina O. Nastri<sup>2</sup>, Maria L.S. Lima<sup>2</sup>,  
Eisa Tahmasbpourmarzouni<sup>3</sup>, Nick Raine-Fenning<sup>4,5</sup>, and  
Wellington P. Martins<sup>2,\*</sup>

There is insufficient evidence available from the currently available RCTs to judge the efficacy or safety of ICSI-AOA on key reproductive outcomes in couples with previous fertilization failure. Such interventions should be further examined by well-designed RCTs before the introduction of ICSI-AOA as a standard treatment.



ORIGINAL ARTICLES: ASSISTED REPRODUCTION



# Does the use of calcium ionophore during artificial oocyte activation demonstrate an effect on pregnancy rate? A meta-analysis

Sughashini Murugesu, M.B.B.Chir.,<sup>a</sup> Srdjan Saso, Ph.D., M.R.C.O.G., M.R.C.S.,<sup>b</sup> Benjamin P. Jones, M.R.C.O.G.,<sup>b</sup> Timothy Bracewell-Milnes, M.R.C.O.G.,<sup>c</sup> Thanos Athanasiou, M.D., Ph.D., M.B.A., F.E.C.T.S., F.R.C.S.,<sup>d</sup> Anastasia Mania, B.Sc., M.Sc., H.C.P.C.,<sup>e</sup> Paul Serhal, M.D., M.R.C.O.G.,<sup>e</sup> and Jara Ben-Nagi, M.D., M.B.B.S., M.R.C.O.G.<sup>e</sup>

<sup>a</sup> Department of Obstetrics and Gynaecology, Hillingdon Hospital, Uxbridge; <sup>b</sup> Division of Surgery and Cancer, Institute of Reproductive and Developmental Biology; <sup>c</sup> Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital; <sup>d</sup> Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College London; and <sup>e</sup> Centre for Reproductive and Genetic Health, London, United Kingdom

We performed a standard meta-analysis to determine the value of calcium ionophore treatment as a method of AOA.

This meta-analysis included a total of **1,521 ICSI cycles spread over 14 studies.**

Focusing on the **primary outcomes**, calcium ionophore use after ICSI treatment significantly increases:

- **Overall pregnancy rate per ET**
- **Live-birth rate per both ET and treatment cycle;**
- **Multiple pregnancy rate per ET.**

Focusing on the **secondary outcomes**, calcium ionophore use after ICSI treatment significantly increases:

- **Fertilization rate,**
- **Cleavage,**
- **Blastocyst formation,**
- **Implantation rate**



## Journal of Obstetrics and Gynaecology

ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/ijog20>

# A retrospective analysis of artificial oocyte activation in patients with low or no fertilisation in intracytoplasmic sperm injection cycles

Kevin K. W. Lam, Jacki Y. Y. Wong, Tak-Ming Cheung, Raymond H. W. Li, Ernest H. Y. Ng & William S. B. Yeung

To cite this article: Kevin K. W. Lam, Jacki Y. Y. Wong, Tak-Ming Cheung, Raymond H. W. Li, Ernest H. Y. Ng & William S. B. Yeung (2021): A retrospective analysis of artificial oocyte activation in patients with low or no fertilisation in intracytoplasmic sperm injection cycles, Journal of Obstetrics and Gynaecology, DOI: [10.1080/01443615.2021.1922878](https://doi.org/10.1080/01443615.2021.1922878)

To link to this article: <https://doi.org/10.1080/01443615.2021.1922878>





# Infertile couples with severe male infertility, poor fertilization

**Table 1.** Laboratory and clinical data of AOA and non-AOA cycles.

	AOA group (n = 34)	Non-AOA group (n = 34)	p Value
Female age (years) <sup>a</sup>	36.4 ± 3.3	36.1 ± 3.7	NS
Number of oocytes per retrieval <sup>a</sup>	10.2 ± 4.9	7.7 ± 4.0	<b>.030</b>
Number of metaphase II oocyte injected per cycle <sup>a</sup>	7.8 ± 4.1	5.7 ± 3.6	<b>.026</b>
Total metaphase II oocyte number	265	188	–
Total normally fertilised oocytes number	138	26	–
Number of normally fertilised oocytes per cycle <sup>a</sup>	4.1 ± 2.8	0.8 ± 1.0	<b>&lt;.001</b>
Normal fertilisation rate (%) <sup>b</sup>	52.1%	13.8%	<b>&lt;.001</b>
Total number of failed fertilisation cycles (%) <sup>c</sup> / number of oocytes injected for these cycles (median ± standard deviation)	4 (11.8%) / 3.5 ± 1.3 oocytes injected	17 (50%) / 3.7 ± 2.2 oocytes injected	<b>&lt;.001</b>
Total cleaved embryos number (%)	136 (98.6%)	25 (96.1%)	NS
Total usable embryos number (%)	98 (72.1%)	22 (88.8%)	NS
Total top quality embryos number (%)	28 (20.6%)	4 (16.0%)	NS
Number of fresh embryo transfer	17	8	–
Number of clinical pregnancy per transfer (%)	5 (29.4%)	1 (12.5%)	NS
Number of clinical pregnancy from subsequent FET cycles	11	0	–
Cumulative clinical pregnancy rate <sup>c</sup>	47.1%	2.9%	<b>&lt;.001</b>
Number of live births	10	1	–
Cumulative live birth rate <sup>c</sup>	29.4%	2.9%	<b>.003</b>

<sup>a</sup>Data expressed as mean ± standard deviation.

<sup>b</sup>Per injected oocytes.

<sup>c</sup>Per oocyte retrieval cycle.

NS: not significant; FET: frozen thawed embryo transfer.

Bold values denote statistical significance at the  $p < .05$ .

**Table 2.** Laboratory and clinical data of AOA cycles using A23187 only and concomitant injection of calcium chloride.

	A23187 group ( <i>n</i> = 9)	A23187 + calcium chloride co-treatment group ( <i>n</i> = 25)	<i>p</i> Value
Female age (years) <sup>a</sup>	38.6 ± 0.6	35.7 ± 0.7	.021
Number of oocytes per retrieval <sup>a</sup>	7.8 ± 4.4	11.1 ± 4.9	NS
Number of metaphase II oocyte injected per cycle <sup>a</sup>	6.1 ± 3.5	8.4 ± 4.2	NS
Total metaphase II oocyte number	55	210	–
Total normally fertilised oocytes number	29	109	–
Normally fertilised oocytes (%) <sup>b</sup>	52.7%	51.9%	NS
Total number of failed fertilisation cycles (%) <sup>c</sup>	2 (22.2%)	2 (8.0 %)	NS
Total cleaved embryos number (%)	29 (100%)	107 (98.2%)	NS
Total usable embryos number (%)	22 (75.9%)	76 (71.0%)	NS
Total top quality embryos number (%)	3 (10.3%)	25 (23.4%)	NS
Number of fresh embryo transfer cycles	5	12	–
Number of clinical pregnancies per embryo transfer (%)	2 (40%)	3 (25%)	NS
Cumulative clinical pregnancy rate (%) <sup>c</sup>	44.4%	40.0%	NS

<sup>a</sup>Data expressed as mean ± standard deviation.

<sup>b</sup>Per injected oocytes.

<sup>c</sup>Per oocyte retrieval cycle.


NS: not significant.

**Table 3.** Obstetrics data of the pregnant patients in the AOA group.

Cases	Gender	Birth weight (g)	Gestation week (weeks + days)	Congenital abnormalities (yes/no)
Patient 1	F (Twins)	2290	33 + 6	No
	F (Twins)	2290	33 + 6	No
Patient 2	M	2300	37	No
Patient 3	M	3110	38 + 2	No
Patient 4	M (Twins)	2345	37 + 3	No
	F (Twins)	2020	37 + 3	No
Patient 5	M	3010	39	No
Patient 6	Miscarriage	/	/	/
Patient 7	Miscarriage	/	/	/
Patient 7	M	3500	40	No
Patient 8	Miscarriage	/	/	/
Patient 9	Miscarriage	/	/	/
Patient 10	Miscarriage	/	/	/
Patient 10	F	3000	39	No
Patient 11	Miscarriage	/	/	/
Patient 12	F	2550	38 + 3	No
Patient 13	F	2800	39 + 4	No
Patient 14	M	3380	39	No



# Ionophore application for artificial oocyte activation and its potential effect on morphokinetics: a sibling oocyte study

Omar Shebl<sup>1</sup> · Philip Sebastian Trautner<sup>1</sup> · Sabine Enengl<sup>1</sup> · Elisabeth Reiter<sup>1</sup> · Christina Allerstorfer<sup>1</sup> · Tamara Rechberger<sup>1</sup> · Peter Oppelt<sup>1</sup> · Thomas Ebner<sup>1</sup> 

Received: 21 July 2021 / Accepted: 1 October 2021  
© The Author(s) 2021

One of the new technologies in the field of medically assisted reproduction from the last decade is time-lapse technology (TLT).



**First**, time-lapse incubators guarantee the safest and most stable embryo culture environment available by simply avoiding extensive exposure outside the incubator.

**Second**, continued embryo monitoring that allows for a 24-h surveillance of the oocytes, zygotes, and embryos facilitates the detection or further investigation of previously unknown phenomena in preimplantation development.

The good practice recommendation paper for the use of TLT by the ESHRE working group on time-lapse technology further highlighted that TLT allows for a more flexible and better management of a laboratory workload.

**Finally**, TLT is an important tool within the framework of existing quality management systems. In fact, it may be used to train embryologists and assess intra- and inter-operator variability with respect to the annotation of morphokinetic parameters.

More importantly, TLT can also be used to identify and monitor in vitro stress that may arise from suboptimal culture conditions. In particular, a large number of consumables or new culture media for testing could interfere with anticipated cleavage timings.

Although subtle changes may have no clinical consequences larger deviations in morphokinetic behavior may reflect severe physiological problems.

**Purpose** To evaluate whether ionophore application at the oocyte stage changes the morphokinetics of the associated embryos in cases of artificial oocyte activation.

**Methods** In a prospective sibling oocyte approach, **78 ICSI patients** with suspected fertilization problems had **half of their MII-oocytes** treated with a **ready-to-use ionophore** (calcimycin) immediately following ICSI (study group). Untreated ICSI eggs served as the control group. Primary analyses focused on morphokinetic behavior and the presence of irregular cleavages. The rates of fertilization, utilization, pregnancy, and live birth rate were also evaluated.

**Results** Ionophore-treated oocytes showed a significantly earlier formation of pronuclei (t2PNa) and a better synchronized third cell cycle (s3) ( $P < .05$ ). The rate of irregular cleavage was unaffected ( $P > .05$ ). **Ionophore treatment significantly improved the overall rates of fertilization ( $P < .01$ ) and blastocyst utilization ( $P < .05$ ).**

**Conclusion** Ionophore application does not negatively affect cleavage timing nor is it associated with irregular cleavage.



Published in final edited form as:

Reprod Biomed Online. 2011 August ; 23(2): 234–244. doi:10.1016/j.rbmo.2011.04.007.

## Methodology matters: IVF versus ICSI and embryonic gene expression

Phillip J. Bridges<sup>a</sup>, Myoungkun Jeoung<sup>a</sup>, Heyoung Kim<sup>a</sup>, Jung Ho Kim<sup>b</sup>, Dong Ryul Lee<sup>b</sup>, CheMyong Ko<sup>a,c</sup>, and Doris J. Baker<sup>a,c</sup>

<sup>a</sup>Division of Clinical and Reproductive Sciences, University of Kentucky, Lexington KY 40536

<sup>b</sup>Fertility Center of CHA Gangnam Medical Center, CHA University 135–080, Seoul, Korea

### In blastocysts derived by:

- ICSI versus IVF: the expression of 197 genes differed ( $P < 0.01$ ).
- ICSI-A versus IVF: the expression of 132 differed ( $P < 0.01$ ).
- ICSI-A versus ICSI: the expression of 65 genes differed ( $P < 0.01$ ).

Technique	Fertilized oocytes cultured	2-cell embryos	Blastocysts
IVF	108	101 (93.52)	79 (78.22)
ICSI	130	111 (85.38)	57 (51.35)
ICSI-A	80	74 (92.50)	40 (54.05)

Data are the sum results from four independent experiments. Values are  $n$  or  $n$  (%).





[www.sciencedirect.com](http://www.sciencedirect.com)  
[www.rbmonline.com](http://www.rbmonline.com)



## EDITORIAL

# A plea for caution and more research in the 'experimental' use of ionophores in ICSI




Jonathan van Blerkom, Jacques Cohen, Martin Johnson

REVIEW

Open Access

# Risk of birth defects in children conceived by artificial oocyte activation and intracytoplasmic sperm injection: a meta-analysis



Rui Long, Meng Wang, Qi Yu Yang, Shi Qiao Hu, Li Xia Zhu\* and Lei Jin\* 

Five studies were included in the final analysis. Compared with conventional ICSI, ICSI-AOA did not increase the birth defects rate (RR = 1.27, 95%CI 0.70–2.28) of children.

**Table 1** Characteristics of included studies of birth defects in babies from conventional ICSI and ICSI-AOA pregnancies

Author(s) Publication year	Location	Study design	Time- period	Length of follow- up	Included study population	Methods of oocyte activation	Conventional-ICSI		ICSI-AOA	
							No. of children (singletons/ multiples) <sup>a</sup>	Children with birth defects	No. of children (singletons/ multiples) <sup>a</sup>	Children with birth defects
Deemeh (2015) [18]	Iran	Historical cohort study	2008– 2010	1–30 months	Live births	ionomycin	89 (67/22)	2 (2.2%)	79 (68/2019)	0 (0%)
Nakajo (2016) [16]	Japan	Retrospective cohort study	1995– 2014	6 years	Live births	Ca <sup>2+</sup> ionophore/ SrCl <sub>2</sub>	1978 (1640/ 338)	75 (3.8%)	62 (51/11)	2 (3.2%)
Miller (2016) [15]	Israel	Retrospective cohort study	2006– 2014	Birth	Live births and TOP	Ca <sup>2+</sup> ionophore	426 (315/ 111)	26 (6.1%)	62 (51/11)	6 (9.7%)
Li B (2019) [17]	China	Retrospective cohort study	2011– 2016	Birth	Live births	ionomycin	2442 (1504/ 938)	31 (1.3%)	95 (59/36)	2 (2.1%)
Kobayashi (2013) [28]	Japan	Retrospective cohort study	2006– 2012	Not known	Live births	ionomycin	571 (Not known)	8 (1.4%)	18 (Not known)	1 (5.5%)
Total							5506	142 (2.6%)	316	11 (3.5%)

ICSI intracytoplasmic sperm injection, AOA artificial oocyte activation, TOP terminal of pregnancy

<sup>a</sup>Multiples including twins and triplets

**Table 2** Number of birth defects in specific organ system from included studies

Author(s)	Specific organ system	Circulatory system	Genitourinary system	Musculoskeletal system	Digestive system	Nervous system	Face	Beckwith-Weidemann syndrome	Poland syndrome
Deemeh [18]	AOA	0	0	0	0	0	0	0	0
	ICSI	1	0	1	0	0	0	0	0
Miller [15]	AOA <sup>a</sup>	4	2	2	0	0	0	1	0
	ICSI <sup>b</sup>	8	5	3	2	3	1	0	0
Li B [17]	AOA	2	0	0	0	0	0	0	0
	ICSI	20	1	3	0	0	3	0	1

ICSI intracytoplasmic sperm injection, AOA artificial oocyte activation

<sup>a</sup>In the AOA group, one case with several structural defects (dysplastic kidney, reflux, ventricular septal defect) and another case with ventricular septal defect, interrupted inferior vena cava and short thumb with low insertion of right hand

<sup>b</sup>In the ICSI group, one case with both hypospadias and ventricular septal defect

Furthermore, in a subgroup analysis, birth defects were classified into two types (chromosomal aberrations and non-chromosomal aberrations) in four studies and no statistical difference were revealed.

**Table 3** Number of children with types of birth defects from included studies

Author(s)	Total number of children		Non-chromosomal aberrations		Chromosomal aberrations	
	ICSI	AOA	ICSI	AOA	ICSI	AOA
Deemeh [18]	89	79	2	0	0	0
Nakajo [16]	1978	62	67	1	8	1
Miller [15]	426	62	19	6	7	0
Li B [17]	2442	95	30	2	1	0

*ICSI* intracytoplasmic sperm injection, *AOA* artificial oocyte activation

## Journal Pre-proof

Artificial oocyte activation to improve reproductive outcomes in couples with various reproductive problems: a retrospective cohort study

Mingrong Lv , Dan Zhang , Xiaojin He , Beili Chen , Qiang Li , Ding Ding , Yan Hao , Rufeng Xue , Dongmei Ji , Weiwei Zou , Huijuan Zou , Yajing Liu , Jianye Wang , Zhaolian Wei , Ping Zhou , Yunxia Cao , Zhiguo Zhang

PII: S1472-6483(20)30001-8  
DOI: <https://doi.org/10.1016/j.rbmo.2020.01.001>  
Reference: RBMO 2324



- 1261 ICSI cycles and 796 ICSI-artificial oocyte activation (ICSI-AOA) cycles.
- The rates of implantation, positive  $\beta$ -hCG, clinical pregnancy, and live birth were significantly improved compared **with the previous cycles**.
- Additionally, compared with previous cycles, the rates of blastulation and high-quality blastocysts were increased significantly for couples with **male factors, young patients with chronic salpingitis, and infertile couples with both factors in the ICSI-AOA cycles**.
- The miscarriage rate was decreased significantly for the couples with male factors, young patients with chronic salpingitis, and patients with polycystic ovary syndrome (PCOS) in the treatment cycles. However, no significant differences were found for fertilization rate, embryo development, or outcomes in patients with primary ovarian insufficiency between the ICSI and ICSIAOA groups.

**Conclusions AOA was able to “rescue” the poor reproductive outcomes in certain types of infertile couples with history of failure pregnancy.**



**Conclusion:** This conclusion may provide clinicians evidence-based support in patient counseling and instruction of the application and safety concern about ICSI-AOA.





